P.100 A randomized, open-label study on the effect of Nipocalimab on vaccine responses in healthy participants

Background: Nipocalimab is a human IgG1 monoclonal antibody targeting FcRn that selectively reduces IgG levels without impacting antigen presentation, T- and B-cell functions. This study describes the effect of nipocalimab on vaccine response. Methods: Open-label, parallel, interventional study rand...

Full description

Saved in:
Bibliographic Details
Published in:Canadian journal of neurological sciences 2025-06, Vol.52 (s1), p.S38-S38
Main Authors: Cossu, M, Bobadilla Mendez, C, Jackson, A, Myshkin, E, Liu, G, Lam, E, Beier, U, Weisel, K, Scott, B, Ait-Tihyaty, M, Sattin, B, Leu, J, Gao, S, Dimitrova, D
Format: Article
Language:English
Subjects:
Abstracts
Evidence
Immunization
Neuromuscular Disease and EMG
Poster Presentations
Tetanus
Vaccines
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!